FDA rejects Singulair-Claritin combination

Apr 30, 2008

The U.S. Food and Drug Administration rejected a proposed pill that would combine the drugs Claritin and Singular, Schering-Plough said.

The drug, a combination of loratadine and montelukast developed in a joint venture between Schering-Plough and Merck Pharmaceuticals, was targeted for patients with allergic rhinitis symptoms and nasal congestion.

The active ingredients of Claritin is loratadine and the active ingredient of Singulair is montelukast sodium. Both drugs are indicated for the relief of symptoms of seasonal allergic rhinitis and perennial allergic rhinitis, the two drug companies said in a statement.

The companies did not explain the FDA's reason for rejecting the drug combo.

Copyright 2008 by United Press International

Explore further: US appeals court upholds delay in Alzheimer's drug swap

Related Stories

NSA winds down once-secret phone-records collection program

5 hours ago

The National Security Agency has begun winding down its collection and storage of American phone records after the Senate failed to agree on a path forward to change or extend the once-secret program ahead of its expiration ...

Pipeline that leaked wasn't equipped with auto shut-off

6 hours ago

The pipeline that leaked thousands of gallons of oil on the California coast was the only pipe of its kind in the county not required to have an automatic shut-off valve because of a court fight nearly three ...

Uber drivers fined in Hungary

6 hours ago

The Hungarian tax authority fined Uber drivers in its first probe against the ride-sharing service which the economy ministry said Saturday "ignores passenger safety" and must be made to follow regulations.

Recommended for you

US appeals court upholds delay in Alzheimer's drug swap

May 22, 2015

A federal appeals court has rejected a drug manufacturer's appeal and affirmed a judge's order that Actavis PLC keep distributing its widely used Alzheimer's medication until after its patent expires this summer.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.